FR16C0028I2 - VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - Google Patents
VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODSInfo
- Publication number
- FR16C0028I2 FR16C0028I2 FR16C0028C FR16C0028C FR16C0028I2 FR 16C0028 I2 FR16C0028 I2 FR 16C0028I2 FR 16C0028 C FR16C0028 C FR 16C0028C FR 16C0028 C FR16C0028 C FR 16C0028C FR 16C0028 I2 FR16C0028 I2 FR 16C0028I2
- Authority
- FR
- France
- Prior art keywords
- viral vectors
- therapeutic methods
- vectors
- methods
- treat disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27906901P | 2001-03-27 | 2001-03-27 | |
PCT/US2002/009512 WO2002076216A1 (en) | 2001-03-27 | 2002-03-27 | Viral vectors and their use in therapeutic methods |
Publications (2)
Publication Number | Publication Date |
---|---|
FR16C0028I1 FR16C0028I1 (en) | 2016-07-22 |
FR16C0028I2 true FR16C0028I2 (en) | 2018-05-11 |
Family
ID=23067509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR16C0028C Active FR16C0028I2 (en) | 2001-03-27 | 2016-06-15 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS |
Country Status (9)
Country | Link |
---|---|
US (6) | US7749745B2 (en) |
EP (1) | EP1381280B1 (en) |
JP (2) | JP4212897B2 (en) |
AT (1) | ATE508635T1 (en) |
AU (1) | AU2002306919B2 (en) |
CA (1) | CA2441663C (en) |
ES (1) | ES2366608T3 (en) |
FR (1) | FR16C0028I2 (en) |
WO (1) | WO2002076216A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
CA2441663C (en) | 2001-03-27 | 2013-01-22 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
JP2005519091A (en) * | 2002-03-01 | 2005-06-30 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Prevention of cancer recurrence and metastasis |
EP1731599A4 (en) * | 2004-03-31 | 2009-12-23 | Tomoki Todo | Method of constructing recombinant herpes simplex virus |
EP1736169B1 (en) * | 2004-03-31 | 2014-03-26 | Tomoki Todo | Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment |
US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
EP2307033A4 (en) * | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | Use of oncolytic herpes viruses for killing cancer stem cells |
US9267151B2 (en) * | 2008-08-20 | 2016-02-23 | Brainco Biopharma, S.L. | STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness |
JPWO2011101912A1 (en) | 2010-02-19 | 2013-06-17 | 国立大学法人 東京大学 | Recombinant herpes virus and pharmaceutical composition comprising recombinant herpes virus |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2753355B1 (en) * | 2011-09-08 | 2018-10-24 | New York University | Oncolytic herpes simplex virus and therapeutic uses thereof |
KR102330183B1 (en) * | 2013-10-28 | 2021-11-23 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Oncolytic hsv vector |
MA39818A (en) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof |
KR20230107375A (en) | 2014-12-18 | 2023-07-14 | 암젠 인크 | Stable frozen herpes simplex virus formulation |
US10967015B2 (en) | 2015-06-15 | 2021-04-06 | New York University | Method of treatment using oncolytic viruses |
WO2017118867A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Use of an oncolytic virus for the treatment of cancer |
ES2919953T3 (en) | 2016-01-27 | 2022-07-29 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
CN109983121A (en) | 2016-06-30 | 2019-07-05 | 昂克诺斯公司 | The pseudotyping oncolytic virus of therapeutical peptide delivers |
JP2020510050A (en) | 2017-03-15 | 2020-04-02 | アムジエン・インコーポレーテツド | Use of an oncolytic virus alone or in combination with a checkpoint inhibitor to treat cancer |
CN106974942A (en) * | 2017-05-03 | 2017-07-25 | 武汉滨会生物科技股份有限公司 | Application of the recombination oncolytic II herpes simplex virus types in anti-lymphadenoma, cancer of the esophagus, breast cancer, pancreatic cancer drug is prepared |
BR112020001559A2 (en) | 2017-07-26 | 2020-08-11 | Oncorus, Inc. | oncolytic viral vectors and uses thereof |
MX2020001328A (en) | 2017-08-03 | 2020-03-20 | Amgen Inc | Interleukin-21 muteins and methods of treatment. |
MA49849A (en) | 2017-08-07 | 2020-06-17 | Amgen Inc | TREATMENT OF NEGATIVE TRIPLE BREAST CANCER OR COLORECTAL CANCER CONTAINING HEPATIC METASTASIS WITH ANTI-PD-L1 ANTIBODY AND ONCOLYTIC VIRUS |
UY37870A (en) | 2017-09-08 | 2019-03-29 | Amgen Inc | KRAS G12C INHIBITORS AND METHODS TO USE THEM FIELD OF THE INVENTION |
WO2019079155A1 (en) | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
JP2019122373A (en) | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | Anti-pd-1 antibodies and methods of treatment |
JP7429046B2 (en) | 2018-03-30 | 2024-02-07 | 具紀 藤堂 | Swelling-inhibiting oncolytic virus |
EP3653716A1 (en) * | 2018-11-19 | 2020-05-20 | HSF Pharmaceuticals | Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore |
JP2022516077A (en) | 2018-12-27 | 2022-02-24 | アムジェン インコーポレイテッド | Freeze-dried virus preparation |
CN113439123A (en) | 2019-03-05 | 2021-09-24 | 安进公司 | Use of oncolytic viruses for the treatment of cancer |
TW202102543A (en) | 2019-03-29 | 2021-01-16 | 美商安進公司 | Use of oncolytic viruses in the neoadjuvant therapy of cancer |
US20230147832A1 (en) * | 2020-01-22 | 2023-05-11 | City Of Hope | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer |
WO2024038857A1 (en) * | 2022-08-16 | 2024-02-22 | 具紀 藤堂 | Pharmaceutical composition containing herpes simplex virus vector |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2659628B1 (en) * | 1990-03-16 | 1992-09-18 | Marin S Communication | BOX OR CASE DEVICE WITH MOBILE COVER. |
CA2039921A1 (en) * | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
GB9102126D0 (en) | 1991-01-31 | 1991-03-13 | Smithkline Beecham Biolog | Novel vaccine |
US5750398A (en) * | 1993-11-30 | 1998-05-12 | David C. Johnson | Vector, element and method for inhibiting immune recognition |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
US6261552B1 (en) * | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
US5824318A (en) * | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
DK1252323T3 (en) * | 2000-01-21 | 2006-04-03 | Biovex Ltd | Virus strains for the oncolytic treatment of cancer |
CA2409932A1 (en) * | 2000-06-01 | 2001-12-06 | Sloan-Kettering Institute For Cancer Research | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
CA2441663C (en) * | 2001-03-27 | 2013-01-22 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
-
2002
- 2002-03-27 CA CA2441663A patent/CA2441663C/en not_active Expired - Lifetime
- 2002-03-27 US US10/107,036 patent/US7749745B2/en active Active
- 2002-03-27 AT AT02753865T patent/ATE508635T1/en not_active IP Right Cessation
- 2002-03-27 EP EP02753865A patent/EP1381280B1/en not_active Expired - Lifetime
- 2002-03-27 WO PCT/US2002/009512 patent/WO2002076216A1/en active Application Filing
- 2002-03-27 JP JP2002574742A patent/JP4212897B2/en not_active Expired - Lifetime
- 2002-03-27 AU AU2002306919A patent/AU2002306919B2/en not_active Expired
- 2002-03-27 ES ES02753865T patent/ES2366608T3/en not_active Expired - Lifetime
-
2008
- 2008-09-22 JP JP2008242828A patent/JP2009060907A/en active Pending
-
2010
- 2010-03-11 US US12/721,599 patent/US8470577B2/en not_active Expired - Lifetime
-
2013
- 2013-06-24 US US13/924,936 patent/US8871193B2/en not_active Expired - Lifetime
-
2014
- 2014-10-27 US US14/524,163 patent/US9555072B2/en not_active Expired - Lifetime
-
2016
- 2016-06-15 FR FR16C0028C patent/FR16C0028I2/en active Active
- 2016-12-19 US US15/383,578 patent/US10532095B2/en not_active Expired - Fee Related
-
2020
- 2020-01-10 US US16/739,890 patent/US20200345835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200345835A1 (en) | 2020-11-05 |
US10532095B2 (en) | 2020-01-14 |
US8470577B2 (en) | 2013-06-25 |
US7749745B2 (en) | 2010-07-06 |
EP1381280A1 (en) | 2004-01-21 |
ES2366608T3 (en) | 2011-10-21 |
WO2002076216A1 (en) | 2002-10-03 |
US8871193B2 (en) | 2014-10-28 |
US20110070262A1 (en) | 2011-03-24 |
US20170290908A1 (en) | 2017-10-12 |
US9555072B2 (en) | 2017-01-31 |
JP2009060907A (en) | 2009-03-26 |
FR16C0028I1 (en) | 2016-07-22 |
US20020187163A1 (en) | 2002-12-12 |
US20150071965A1 (en) | 2015-03-12 |
CA2441663C (en) | 2013-01-22 |
EP1381280A4 (en) | 2006-06-14 |
JP2004528836A (en) | 2004-09-24 |
US20130280299A1 (en) | 2013-10-24 |
JP4212897B2 (en) | 2009-01-21 |
AU2002306919B2 (en) | 2007-11-22 |
EP1381280B1 (en) | 2011-05-11 |
ATE508635T1 (en) | 2011-05-15 |
CA2441663A1 (en) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR16C0028I2 (en) | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS | |
DK1556021T3 (en) | Pharmaceutical compositions comprising flavonoids and menthol as well as methods of treatment using said compositions | |
NO20053817D0 (en) | Preparations and Methods for Antiviral Combination Therapy. | |
DK1368060T3 (en) | HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease | |
NO20041917L (en) | Specific agents that bind human angiopoietin-2 | |
BR0309665A (en) | Treatment of alpha-galactosidase deficiency at | |
BRPI0411900A (en) | antiviral compounds and methods | |
DE60327999D1 (en) | AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES | |
ATE376832T1 (en) | DELAYED RELEASE FORMULATIONS OF OXYMORPHONE | |
BRPI0412845A (en) | herpes virus, use of a virus, pharmaceutical composition, and method of treating a tumor in an individual in need thereof | |
DE60137337D1 (en) | PREVENTIVE AND THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST VACCINIAVIRUSANTIGENE | |
WO2003032916A3 (en) | Organosulfur inhibitors of tyrosine phosphatases | |
HUP0303917A2 (en) | Combinations of sterol absorption inhibitir(s) with blood modifier(s) and their use for treating vascular conditions | |
CY1107531T1 (en) | USE OF PROTECTION ANALYTES FOR THE TREATMENT OF DRY EYE DISORDERS | |
DK1097173T3 (en) | Use of IL-2 peptides and derivatives thereof as therapeutic agents | |
MXPA04006572A (en) | Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections. | |
CL2004000261A1 (en) | PROCEDURE FOR THE ELIMINATION OF VIRUSES IN THERAPEUTIC APPLICATION FIBRINOGEN SOLUTIONS. | |
DE602005016552D1 (en) | PARAPOCK VIRUS IN COMBINATION WITH OTHER ANTIVIRAL AGENTS FOR THE TREATMENT OF HIV / AIDS | |
TR200200278T2 (en) | Calcilitic compositions | |
NO20051301L (en) | Proteintyrosinforfataseinhibitorer | |
DE602004019541D1 (en) | CYCLOALKYLÄBÜ CONDENSED INDOLE | |
EA200000909A1 (en) | FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE | |
DK1461042T3 (en) | Use of desoxypeganine in the treatment of clinical depression | |
NO20005548L (en) | Mykobakterieinhibitorer | |
DK1377667T3 (en) | Fusion proteins for specific treatment of cancer and autoimmune diseases |